Zheng Wei, Zhao Yao, Luo Qun, Zhang Yang, Wu Kui, Wang Fuyi
Beijing National Laboratory for Molecular Sciences; CAS Key Laboratory of Analytical Chemistry for Living Biosystems; National Centre for Mass Spectrometry in Beijing; Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China.
University of Chinese Academy of Sciences, Beijing 100049, P.R. China.
Curr Top Med Chem. 2017 Nov 20;17(28):3084-3098. doi: 10.2174/1568026617666170707124126.
There is a great demand for the development of novel anticancer drugs, due to the increasing morbidity and high mortality of cancer. To date, chemotherapy still plays a central role in the clinical treatment of cancer, but this role is being reduced by targeted therapies. Since cancer is a complicated and multiple genes involved disease, drugs that act at multiple targets can enhance efficacy and lower drug resistance, and are thought to be the future of novel anticancer drug development. In this paper, we discuss the recent development of "single molecule, multi-target" anticancer agents that combine two or more pharmacophores in a single molecule, including organic multitargeted anticancer agents and metal based complexes such as platinum, ruthenium, iridium and rhodium complexes. These efforts will contribute to clinical cancer therapy and benefit patients in the future.
由于癌症发病率的不断上升和高死亡率，对新型抗癌药物的开发有巨大需求。迄今为止，化疗在癌症临床治疗中仍起着核心作用，但这一作用正被靶向治疗所削弱。由于癌症是一种涉及复杂多基因的疾病，作用于多个靶点的药物可以提高疗效并降低耐药性，被认为是新型抗癌药物开发的未来方向。在本文中，我们讨论了“单分子、多靶点”抗癌剂的最新进展，这些抗癌剂在单个分子中结合了两个或更多药效基团，包括有机多靶点抗癌剂和基于铂、钌、铱和铑等金属的配合物。这些努力将有助于未来的癌症临床治疗并使患者受益。
